BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2288720)

  • 1. Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by alpha-interferon and dacarbazine--a preliminary report.
    Merimsky O; Inbar M; Shiloni E; Ron I; Chaitchik S
    Mol Biother; 1990 Dec; 2(4):208-10. PubMed ID: 2288720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
    Neri B; Vannozzi L; Fulignati C; Pantaleo P; Pantalone D; Paoletti C; Perfetto F; Turrini M; Mazzanti R
    Cancer Invest; 2006; 24(5):474-8. PubMed ID: 16939954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
    Tessier MH; Mansat E; Legoux B; Litoux P; Dreno B
    Ann Dermatol Venereol; 1996; 123(9):538-42. PubMed ID: 9615103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Our experience with interferon alpha: metastatic malignant melanoma.
    Merimsky O; Chaitchik S
    Mol Biother; 1992 Sep; 4(3):135-8. PubMed ID: 1445667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.
    Stoter G; Shiloni E; Aamdal S; Cleton FJ; Iacobelli S; Bijman JT; Palmer P; Franks CR; Rodenhuis S
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S41-3. PubMed ID: 2697578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combination of dacarbazine, vindesine and interferon alpha in the treatment of metastatic melanoma].
    Mansat-Krzyzanowska E; Dreno B
    Ann Dermatol Venereol; 1994; 121(12):884-7. PubMed ID: 7632005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
    Shiloni E; Pouillart P; Janssens J; Splinter T; Di Peri T; Symann M; Roest GJ; Palmer PA; Franks CR
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S45-9. PubMed ID: 2697579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
    In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
    Célérier P; Dreno B; Bureau B; Litoux P
    Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.
    Legha SS; Buzaid AC
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):27-32. PubMed ID: 8054006
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
    Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
    Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of fibroblast interferon (HuIFN beta), carboxamide (DTIC), and cimetidine for advanced malignant melanoma.
    Abdi EA; McPherson TA; Tan YH
    J Biol Response Mod; 1986 Oct; 5(5):423-8. PubMed ID: 3772395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha and interleukin-2 in the treatment of renal cell cancer.
    Holdener EE; Emmons RP; Brunda M; Evans L; Levitt D
    Prog Clin Biol Res; 1990; 348():61-9. PubMed ID: 2201034
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose-response relationship to dacarbazine demonstrated in a patient with malignant melanoma.
    Hoelzer KL; Harrison BR; Luedke DW; Mahanta B
    Cancer Treat Rep; 1986 Oct; 70(10):1211-2. PubMed ID: 3756941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone].
    Chauvergne J; Bui NB; Cappelaere P; Gary-Bobo J; Guerrin J; Armand JP; Durand M
    Sem Hop; 1982 Dec; 58(46):2697-701. PubMed ID: 6297068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
    Bartell HL; Bedikian AY; Papadopoulos NE; Dett TK; Ballo MT; Myers JN; Hwu P; Kim KB
    Head Neck; 2008 Dec; 30(12):1592-8. PubMed ID: 18798304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
    Legha SS; Ring S; Eton O; Bedikian A; Plager C; Papadopoulos N
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S9-15. PubMed ID: 9457387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.